ACGL — Arch Capital Group Ltd.

Sell-side is constructive: 16 Buy / 16 Hold / 2 Sell, consensus target ~$114 (range $104–$126), with JPMorgan at $118, Cantor at $110 and BMO at $102 after the Q2 beat. The tape disagrees. As of 2026-09-13 the stock was -2.05% over one week and -1.23% over one month, RSI(14) sat at 40.12, and price was 2.43% below its 20-day and 3.84% below its 50-day average. Investors are crediting the operating beat but discounting the softening premium-pricing cycle and the fact that 2026 first-half EPS ($2.88, $3.00) is running below the comparable 2025 quarters ($3.23, $3.56).

Decelerating top line, plateaued earnings, stable margins. Revenue climbed through the hard market from $3.29B (Q3 2023) to a $5.39B peak (Q4 2025), then rolled over: Q2 2026 revenue of $4.47B was ~10% below Q2 2025's $4.97B, and TTM revenue of ~$19.2B is roughly flat versus the prior TTM — a deceleration, not a collapse, and part of the swing is investment-gain volatility inside the revenue line rather than an underwriting demand shock. EPS ran 2.92 / 3.30 / 2.56 / 2.41 across 2024, dipped to $1.48 in Q1 2025 (catastrophe quarter), then printed 3.23 / 3.56 / 3.35 before settling at 2.88 / 3.00 in the first half of 2026 — a plateau about 10% below the 2025 peak (the Q4 2023 $6.12 is a one-off: net income $2,334M versus operating income $1,086M). Margins are the steadier read, with operating margin at 27.3% in Q2 2026 versus 28.4% a year earlier, and cash generation is enviably consistent — quarterly operating cash flow between $1.18B and $2.17B for twelve straight quarters, $6.06B TTM. Verdict: a maturing hard-market cycle inside a still-high-quality franchise (82.5% ex-catastrophe combined ratio in Q2 2026), not a structural breakdown.

On trailing numbers ACGL screens cheap: 7.4x TTM EPS of $13.67, 1.37x book, 1.75x sales, PEG 0.24 — and the deterministic score's overlay labels it 'Cheap vs. its own history' (5-year average P/E 9.36x, average P/S 2.03x). Strip out the peak, though: on consensus forward EPS of $9.39 the multiple is 10.2x, above the 7.4x trailing, because the Street expects earnings to fall roughly 30% from the TTM figure. Against a 5-year average P/E of 9.36x that is roughly in line, not a bargain; the real discount is on price-to-book (1.4x today versus the 1.3–1.9x ACGL has typically traded at) against an 18.2% ROE. One data caveat: the reported 5.16% dividend yield is almost certainly an artifact — Arch returns capital through buybacks ($1.2B in Q2 2026 alone), not a meaningful common dividend, so no income thesis should be built on that number.

This is the crux. As of 2026-09-13, at $96.09, the stock is not mispricing a turnaround that hasn't shown up — it is pricing in a peak-earnings-to-normalized transition that is already visible, with 2026 first-half EPS of $2.88 / $3.00 versus $3.23 / $3.56 a year earlier and a consensus forward figure of $9.39 sitting 31% below TTM EPS of $13.67. At ~10.2x forward earnings the market has largely acknowledged that decline, which caps downside if estimates hold; the asymmetry is that the sell-side number may be too harsh given $6.06B of TTM free cash flow, a share count shrinking with $1.2B/quarter of buybacks, and favorable reserve development (+$165M pre-tax in Q2 2026). What breaks the setup is a further leg down in forward estimates (toward $8.00): the multiple then expands against a shrinking E and the stock stalls even while the trailing P/E looks 'cheap.' Trade estimate revisions here, not the headline trailing multiple.

As of 2026-09-13: RSI(14) at 40.12 — weak but not oversold — with price 2.43% below the 20-day and 3.84% below the 50-day average while tagging the 200-day (0.10% below). Momentum has faded from a three-month gain of +4.83% to a six-month gain of just +2.80%, including -2.05% in the last week. This is a range-bound stock coiling on its long-term trend line rather than a broken chart. Entry implication: ~$96 is the decision point — a weekly close below the 200-day opens the $88–92 zone (with the $82.45 52-week low further down), while reclaiming the 50-day (~$100) restores the uptrend. Given RSI 40 and the 200-day test, averaging in around here is defensible for a long-term holder, but there is no momentum confirmation, so a decisive break lower should be respected. Beta of 0.28 means this name trades on its own fundamentals, not the index.

• Elevated global interest rates continue to power net investment income on a large investment float — a real book-value tailwind, but one that reverses if rates fall sharply.
• The P&C/reinsurance pricing cycle is rolling over after the 2022–2025 hard market; rate deceleration in property-catastrophe and specialty lines is the single biggest swing factor for 2027 revenue and margins.
• Social inflation and rising liability loss costs keep long-tail casualty reserve adequacy a live question — ACGL has benefited from favorable development recently, and that can reverse.
• Catastrophe activity and climate volatility: Q3 is peak North American windstorm season (Q1 2025's wildfire quarter cut EPS to $1.48 from a ~$3 run-rate), so a single event can move a quarter's results.
• Housing and mortgage-credit conditions directly hit the Mortgage segment, which is a differentiated, high-margin earnings stream relative to pure-play P&C peers and remains resilient under sustained higher borrowing costs.

• Q3 2026 earnings in late October 2026 — peak wind-season catastrophe losses versus favorable prior-year development, combined ratio, and sequential book value growth.
• Management appearances at the Barclays Global Financial Services Conference (Sept 16, 2026) and the BofA Securities Financial CEO Conference (Sept 22, 2026), where pricing, margin and capital-deployment commentary will set the tone.
• January 2027 reinsurance renewals — the clearest read on whether the pricing softening is stabilizing or accelerating.
• Continued aggressive buybacks ($1.2B in Q2 2026 alone), which shrink the share count and mechanically support EPS and BVPS.
• New CEOs of the Global Reinsurance and Global Mortgage units (announced mid-June 2026), whose underwriting/strategic posture will shape segment growth.

• Further premium-rate softening in reinsurance and specialty lines compressing underwriting margins into 2027 — the clearest threat to the franchise.
• Adverse casualty reserve development reversing the recent favorable trend (+$165M pre-tax in Q2 2026), which would hit both earnings and book value credibility.
• A large single-event or aggregate catastrophe loss; Q1 2025 already showed the downside (EPS $1.48 versus a ~$3 run-rate).
• The consensus forward EPS of $9.39 versus $13.67 TTM — if that estimate is right or gets cut again, the low trailing P/E is a value trap, not a discount.
• Balance-sheet shift: long-term debt jumped to $4.29B at 6/30/26 from $2.73B at 3/31/26, raising leverage and interest expense (D/E is still modest at 0.178).
• Falling interest rates reducing net investment income, which has been a structural tailwind to book-value compounding.

ACGL is a genuinely high-quality specialty insurer — 18.2% ROE, $6.06B TTM free cash flow, cash earnings running ahead of reported earnings (accruals ratio -0.31%), an 82.5% ex-catastrophe combined ratio, book value per share up 2.8% sequentially to $68.04, and $1.2B of stock repurchased in a single quarter — trading at ~1.4x book and ~10x forward earnings. The catch is the cycle, not the company: reinsurance/specialty pricing is softening, revenue is down ~10% year over year, and consensus expects forward EPS of $9.39 versus $13.67 trailing, which makes the headline 7.4x P/E a peak-earnings illusion. My fair value lands near $108 against $96.09 on 2026-09-13 — roughly 12% of upside, real but not compelling. That supports treating this as quality-at-a-fair-price for patient capital rather than a screaming buy or a momentum trade, consistent with the deterministic score's Fair Fundamentals band and a Neutral lean.

Blend of two methods. (1) 10.0x a normalized EPS of ~$10.70 — placed between the $12.79 TTM run-rate (flattered by ~$165M/quarter of favorable reserve development and light catastrophes) and the $9.39 consensus forward figure — gives ~$107. (2) 1.55x an estimated year-end 2026 book value of ~$70/share (BVPS $68.04 at 6/30/26, warranted by a ~15% sustainable ROE against a ~9–9.5% cost of equity for a low-beta, well-capitalized specialty insurer) gives ~$108.5. The ~$108 average is ~12% above the 2026-09-13 price of $96.09 and modestly below the $113.67–$114.17 sell-side consensus target.